###### Strengths and limitations of this study

-   This is one of the first studies worldwide focusing on the incidence of multimorbidity rather than on the prevalence of multimorbidity. Prevalence reflects the effect of incidence as well as of survival after the onset of multimorbidity. We used a simple definition of incident multimorbidity that can be replicated in other populations.

-   This study covered an entire geographically defined population and used a unique records-linkage system. Persons were followed historically over 14 years. None of the data were derived from self-report or interviews.

-   Studies of multimorbidity require the definition of the number of conditions considered, of the time window of occurrence and of the source of data (medical records vs interview). We used the 20 conditions recommended by the US Department of Health and Human Services. These 20 conditions represent a first consensus list; however, not all of the conditions have the same impact on the complexity of care or on the quality of life of patients.

-   Potential limitations of this study include the uncertain validity of diagnostic codes, the possible incompleteness of information due to in or out migration and the inability to generalise our findings to other populations with different demographical or social characteristics.

-   Replication of this study in other populations in the USA and worldwide will allow for useful comparisons.

Introduction {#s1}
============

The demographic expansion of the elderly population and the improvements in survival of people affected by chronic conditions have caused a dramatic rise in the number of people living with multimorbidity (≥2 chronic conditions). In the USA, the prevalence of multimorbidity among Medicare recipients increases from 62% at age 65--74 years to 82% at ages 85 years and older.[@R1] The monetary costs associated with managing patients with multiple chronic conditions are overwhelming.[@R2] In addition, fragmented healthcare in patients with multimorbidity causes a particularly high risk for complications and a lower quality of life.[@R5] [@R6]

Several studies have described the prevalence of multimorbidity in a wide range of populations.[@R1] [@R7] Additional studies have focused on how to manage patients with multiple chronic conditions.[@R13] [@R14] However, in 2010 the US Department of Health and Human Services (US-DHHS) highlighted the critical need to identify groups of individuals at higher risk of developing multimorbidity (first appearance of multimorbidity). Such studies of incident multimorbidity are essential to identify patterns of disease accumulation and to identify the populations at high risk of developing multimorbidity. For example, multimorbidity is highly prevalent in the elderly; however, many of the processes that lead to multimorbidity begin at much earlier ages. Therefore, data on the ages at which multimorbidity begins and on the patterns of accumulation of conditions over time are urgently needed to develop focused interventions to prevent multimorbidities and their adverse health outcomes.[@R15]

Unfortunately, there are currently no population-based data on the incidence of multimorbidity in the USA across all ages, even though multimorbidity is a high public health priority for the nation.[@R15] The Rochester Epidemiology Project (REP) medical records-linkage system captures long-term medical information on a stable population and is therefore uniquely positioned to study the incidence of multimorbidity. In a previous paper, we described in detail the patterns of prevalent multimorbidity in this population.[@R16] In this study, we further leveraged this data resource to examine the incidence of multimorbidity across all ages, separately in men and women and in three ethnic groups.[@R17]

Methods {#s2}
=======

Study population {#s2a}
----------------

The REP has tracked and linked healthcare information for the population of Olmsted County, Minnesota, USA since 1966.[@R17] The vast majority of medical care in this community is currently provided by a few healthcare institutions: Olmsted Medical Center and its affiliated hospital, Mayo Clinic and its two affiliated hospitals, the Rochester Family Medicine Clinic and a few smaller care facilities. The healthcare records from these institutions are linked together through the REP records-linkage system.[@R17] Persons are considered residents of Olmsted County at the time of each healthcare visit based on their address. Over the years, this address information has been accumulated and is used to define who resided in Olmsted County at any given point in time since 1966 (REP Census). The population counts obtained by the REP Census are similar to those obtained by the US Census, indicating that virtually the entire population of the county is captured by the system.[@R18] We used the REP Census to identify all individuals who resided in Olmsted County on 1 January 2000 (baseline date); however, we included only individuals who had not refused permission to use their medical records for research (Minnesota Research Authorization).[@R18] [@R21] [@R22]

Definition of incident multimorbidity {#s2b}
-------------------------------------

We focused on 20 selected chronic conditions recommended by the US-DHHS for studying multimorbidity.[@R23] [@R24] The list of the 20 conditions and the corresponding International Classification of Diseases Ninth Edition (ICD-9) codes used in this study are provided in online supplementary table SA.[@R23] [@R24] We first identified all ICD-9 codes associated with these 20 chronic conditions that occurred in the population between 1 January 1995 and 31 December 1999 (5 years before the baseline date, 1 January 2000). Persons who did not have any ICD-9 codes for a given condition were assumed to not have the condition of interest. By contrast, residents were defined as having a chronic condition if they had at least two ICD-9 codes for that condition separated by more than 30 days, and the incidence date was assigned at the time they received a second diagnostic code.

Persons who had 2 or more of the 20 conditions at baseline were considered to have prevalent multimorbidity and were therefore excluded from incidence analyses of 2 chronic conditions (dyads). Similarly, persons who had 3 or more of the 20 conditions at baseline were excluded from incidence analyses of 3 chronic conditions (triads). All persons in this fixed population cohort were followed historically through the REP records-linkage system for approximately 14 years to study the emergence of new conditions.

Statistical analyses {#s2c}
--------------------

All persons in the cohort were followed from 1 January 2000 through the last contact with the records-linkage system (the earliest of death date, last medical visit date or 31 December 2013). The incidence of each of the 20 chronic conditions was calculated among persons free of that condition at baseline. Persons contributed person-years to the denominator for the incidence of two conditions (development of a second condition in a dyad) only during the time when they had zero or one chronic conditions, whereas persons contributed person-years to the denominator for the incidence of three chronic conditions (development of a third condition in a triad) only when they had zero, one or two chronic conditions. Although the majority of people accumulated conditions one-at-a-time, some participants jumped from zero to two conditions, or from one to three, or even from zero to three conditions. For example, a person previously considered free of all of the 20 conditions who was diagnosed with hyperlipidaemia, hypertension and depression during one visit was counted as having three incident dyads and one incident triad on the same date.

Incidence rates were reported separately by age (using seven age strata or splitting the entire population in 0--64 and ≥65 years), sex and ethnicity, and were directly standardised by age and sex to the total US 2010 Decennial Census after removing projected prevalence (see online supplementary table SB). Since the study covered the target population completely, and no sampling was involved, CIs were not included in the tables.[@R25] [@R26] Ethnicity data were not available for 9176 people (7.4% of the cohort). These individuals were included in the overall and age-specific and sex-specific analyses, but not in the ethnicity-specific analyses.

Although the 20 conditions proposed by the US-DHHS represent a national consensus,[@R15] some of the conditions may have a different prognostic impact than others. For example, hyperlipidaemia and hypertension often occur together and tend to remain asymptomatic. Therefore, we performed a set of sensitivity analyses combining hyperlipidaemia and hypertension as a single chronic condition. The date of incidence for the single chronic condition of hyperlipidaemia and/or hypertension was defined as the date the person first met criteria for either of these conditions.

Results {#s3}
=======

Description of the Olmsted County population {#s3a}
--------------------------------------------

The REP Census identified 129 311 Olmsted County, Minnesota residents on 1 January 2000 compared with 124 277 individuals counted by the 2000 US Census (104.1%); 123 716 persons provided Minnesota research authorisation for medical record research (95.7%) and were included in our analyses. A total of 17 655 people (14.3%) had two or more conditions at the baseline date and 9368 (7.6%) had three or more conditions (prevalent multimorbidity). Overall, we observed a total of 1 334 906 person-years of follow-up; however, as expected, the length of follow-up varied by age group. For example, median follow-up was 13.1 years in persons aged 0--19 years at baseline, 12.3 years in persons aged 70--79 years at baseline and 4.9 years in persons aged 80 years or older at baseline.

[Figure 1](#BMJOPEN2014006413F1){ref-type="fig"} and online supplementary table SC report the incidence of each of the 20 chronic conditions considered separately by age and sex. The incidence of most of the chronic conditions increased steeply with older age. However, the incidence of asthma, substance abuse disorders, hepatitis, autism spectrum disorder and infection with HIV was higher in the younger population compared to persons older than 60 years. The incidence of depression increased from ages 0--19 to 20--39 years, declined from 40--49 to 60--69 years, and increased sharply again thereafter. The incidence of most conditions was higher in men compared to women of the same age; however, women had a higher incidence of depression, arthritis, asthma and osteoporosis. The incidence curves in men and women crossed at age 50--59 years for cancer and at age 60--69 years for chronic obstructive pulmonary disease ([figure 1](#BMJOPEN2014006413F1){ref-type="fig"}).

![Age-specific and sex-specific incidence rates (per 1000 person-years) of the 20 chronic conditions considered separately. The 20 panels are presented by rows in decreasing order of frequency (by overall age-standardised and sex-standardised prevalence).[@R16]](bmjopen2014006413f01){#BMJOPEN2014006413F1}

Incidence of multimorbidity by age, sex and ethnicity {#s3b}
-----------------------------------------------------

[Figure 2](#BMJOPEN2014006413F2){ref-type="fig"} shows the age-specific incidence rates of multimorbidity in men and women separately (A and C), and in three ethnic groups (B and D). The incidence of two chronic conditions and the incidence of three chronic conditions both increased steeply with older age ([table 1](#BMJOPEN2014006413TB1){ref-type="table"}, [table 2](#BMJOPEN2014006413TB2){ref-type="table"}, and [figure 2](#BMJOPEN2014006413F2){ref-type="fig"}). For example, the incidence of two chronic conditions in men was 6.5/1000 person-years in persons who were ages 0--19 years, and 260.0/1000 in persons who were ≥80 years. The overall incidence of two chronic conditions was slightly higher in women compared to men (overall standardised incidence rates 38.8 vs 35.5/1000 person-years; [table 1](#BMJOPEN2014006413TB1){ref-type="table"}). The incidence of two chronic conditions was higher in Blacks compared to Whites, but lower in Asians compared to Whites (see standardised incidence rates in [table 1](#BMJOPEN2014006413TB1){ref-type="table"} and [figure 2](#BMJOPEN2014006413F2){ref-type="fig"}). We observed similar patterns for the development of three chronic conditions (see standardised incidence rates in [table 2](#BMJOPEN2014006413TB2){ref-type="table"} and [figure 2](#BMJOPEN2014006413F2){ref-type="fig"}). The overall incidence of three conditions was similar in men and women (standardised incidence rates 25.5/1000 person-years in men vs 26.6/1000 person-years in women); however, it was higher in Blacks and lower in Asians, compared to Whites ([table 2](#BMJOPEN2014006413TB2){ref-type="table"} and [figure 2](#BMJOPEN2014006413F2){ref-type="fig"}).

###### 

Incidence of the second of two chronic conditions (per 1000 person-years) in persons living in Olmsted County, Minnesota, by age, sex and ethnicity

  Ethnicity age (years)   Men      Women                                        
  ----------------------- -------- --------- --------------- -------- --------- ---------------
  All ethnic groups                                                             
   0--19                  18 879   140 653   6.5 (921)       18 024   134 725   8.5 (1151)
   20--39                 27 732   151 734   17.2 (2613)     28 571   158 252   25.1 (3972)
   40--49                 16 396   82 324    43.6 (3590)     16 713   85 660    45.8 (3920)
   50--59                 11 779   52 085    85.2 (4436)     12 398   55 270    84.6 (4674)
   60--69                 5218     19 653    139.4 (2739)    5603     21 246    135.3 (2874)
   70--79                 1775     5451      209.9 (1144)    2184     6660      202.0 (1345)
   ≥80                    531      1589      260.0 (413)     1016     2887      277.1 (800)
   0--64                  50 648   439 254   29.7 (13 059)   51 056   447 399   34.2 (15 319)
   ≥65                    3794     14 236    196.5 (2797)    4636     17 300    197.5 (3417)
  All ages                52 479   453 489   35.0 (15 856)   53 582   464 699   40.3 (18 736)
  Standardised†           --       --        35.5            --       --        38.8
  Blacks                                                                        
   0--19                  877      6411      5.5 (35)        749      5362      6.0 (32)
   20--39                 1099     6178      16.5 (102)      934      5647      23.0 (130)
   40--49                 429      1836      63.2 (116)      324      1392      61.8 (86)
   50--59                 180      683       105.3 (72)      139      513       121.0 (62)
   60--69                 60       223       134.8 (30)      47       150       193.2 (29)
   70--79                 18       71        140.1 (10)      23       60        200.4 (12)
   ≥80                    4        11        274.0 (3)       3        5         580.3 (3)
   0--64                  1848     15 240    22.0 (335)      1563     13 010    25.5 (332)
   ≥65                    48       173       190.8 (33)      37       118       185.7 (22)
  All ages                1873     15 413    23.9 (368)      1587     13 128    27.0 (354)
  Standardised†           --       --        38.9            --       --        48.5
  Asians                                                                        
   0--19                  818      6331      3.5 (22)        826      6299      5.6 (35)
   20--39                 1090     6372      15.1 (96)       1168     7167      14.6 (105)
   40--49                 534      2464      39.8 (98)       591      2869      33.8 (97)
   50--59                 339      1588      71.8 (114)      376      1687      79.4 (134)
   60--69                 159      592       120.0 (71)      185      570       161.3 (92)
   70--79                 51       163       140.8 (23)      74       177       271.6 (48)
   ≥80                    21       60        216.6 (13)      40       92        358.1 (33)
   0--64                  1897     17 137    21.6 (370)      1997     18 399    23.3 (429)
   ≥65                    114      433       154.7 (67)      159      463       248.4 (115)
  All ages                1954     17 571    24.9 (437)      2105     18 862    28.8 (544)
  Standardised†           --       --        29.5            --       --        34.9
  Whites                                                                        
   0--19                  14 956   119 686   6.8 (818)       14 414   114 906   9.0 (1032)
   20--39                 21 792   128 801   17.9 (2303)     23 214   135 903   26.5 (3599)
   40--49                 14 426   74 921    43.6 (3269)     15 088   79 123    46.1 (3646)
   50--59                 10 795   48 361    85.8 (4149)     11 520   51 901    84.8 (4399)
   60--69                 4823     18 362    140.4 (2578)    5221     20 075    134.7 (2704)
   70--79                 1653     5090      212.6 (1082)    2030     6301      200.9 (1266)
   ≥80                    497      1495      262.8 (393)     953      2754      274.5 (756)
   0--64                  40 703   383 410   31.2 (11 952)   42 149   394 566   35.9 (14 170)
   ≥65                    3517     13 306    198.4 (2640)    4317     16 398    197.1 (3232)
  All ages                42 382   396 716   36.8 (14 592)   44 465   410 964   42.3 (17 402)
  Standardised†           --       --        36.0            --       --        39.4

\*Incidence rates are reported per 1000 person-years.

†Incidence rates were directly standardised to the total US population from the 2010 US Decennial Census after removing the number of people with prevalent multimorbidity (≥2 chronic conditions) as projected from our previous study (see online supplementary table SB).[@R16]

###### 

Incidence of the third of three chronic conditions (per 1000 person-years) in persons living in Olmsted County, Minnesota, by age, sex and ethnicity

  Ethnicity age (years)   Men      Women                                        
  ----------------------- -------- --------- --------------- -------- --------- ---------------
  All ethnic groups                                                             
   0--19                  19 029   144 025   1.3 (186)       18 203   138 055   2.0 (282)
   20--39                 28 721   162 693   6.9 (1123)      30 135   177 878   10.9 (1944)
   40--49                 17 901   95 582    22.6 (2157)     18 824   103 400   24.2 (2507)
   50--59                 14 398   69 907    52.8 (3688)     15 475   76 247    51.5 (3930)
   60--69                 7517     31 617    99.5 (3146)     8313     35 342    96.7 (3416)
   70--79                 3109     10 639    169.7 (1805)    3899     13 653    156.4 (2136)
   ≥80                    992      3230      218.9 (707)     1970     6414      230.6 (1479)
   0--64                  53 073   491 536   18.0 (8852)     54 280   517 164   20.2 (10 432)
   ≥65                    5938     26 156    151.4 (3960)    7706     33 825    155.6 (5262)
  All ages                55 898   517 693   24.7 (12 812)   58 450   550 989   28.5 (15 694)
  Standardised†           --       --        25.5            --       --        26.6
  Blacks                                                                        
   0--19                  879      6530      1.1 (7)         751      5458      1.1 (6)
   20--39                 1123     6428      8.6 (55)        960      6032      9.4 (57)
   40--49                 460      2126      34.8 (74)       373      1723      41.2 (71)
   50--59                 218      952       69.3 (66)       173      737       69.2 (51)
   60--69                 81       312       96.1 (30)       70       241       132.8 (32)
   70--79                 27       108       129.4 (14)      28       84        191.0 (16)
   ≥80                    5        23        172.3 (4)       5        9         321.2 (3)
   0--64                  1883     16 227    13.3 (216)      1602     14 101    14.5 (205)
   ≥65                    58       252       135.1 (34)      54       183       169.2 (31)
  All ages                1911     16 479    15.2 (250)      1633     14 284    16.5 (236)
  Standardised†           --       --        28.2            --       --        34.8
  Asians                                                                        
   0--19                  823      6419      0.6 (4)         832      6442      1.6 (10)
   20--39                 1109     6747      6.2 (42)        1206     7587      4.6 (35)
   40--49                 574      2841      18.7 (53)       651      3327      20.7 (69)
   50--59                 390      1942      44.8 (87)       439      2191      46.1 (101)
   60--69                 203      830       78.3 (65)       254      966       97.3 (94)
   70--79                 80       259       138.8 (36)      110      353       141.5 (50)
   ≥80                    32       84        202.0 (17)      84       228       241.2 (55)
   0--64                  1940     18 472    12.2 (225)      2074     20 167    12.9 (261)
   ≥65                    165      650       121.5 (79)      258      929       164.7 (153)
  All ages                2027     19 122    15.9 (304)      2235     21 096    19.6 (414)
  Standardised†           --       --        21.1            --       --        23.2
  Whites                                                                        
   0--19                  15 088   122 717   1.3 (160)       14 576   117 885   2.2 (259)
   20--39                 22 681   138 725   7.1 (990)       24 638   154 160   11.7 (1799)
   40--49                 15 811   87 199    22.7 (1978)     17 025   95 693    24.1 (2308)
   50--59                 13 262   65 243    53.1 (3464)     14 443   71 770    51.7 (3714)
   60--69                 7028     29 816    100.8 (3005)    7796     33 477    96.9 (3244)
   70--79                 2930     10 061    171.9 (1729)    3680     13 006    157.2 (2045)
   ≥80                    942      3093      219.5 (679)     1848     6105      231.0 (1410)
   0--64                  42 953   432 089   19.0 (8213)     45 157   459 919   21.2 (9761)
   ≥65                    5572     24 764    153.1 (3792)    7224     32 177    155.9 (5018)
  All ages                45 583   456 853   26.3 (12 005)   49 033   492 097   30.0 (14 779)
  Standardised†           --       --        25.7            --       --        27.0

\*Incidence rates are reported per 1000 person-years.

†Incidence rates were directly standardised to the total US population from the 2010 US Decennial Census after removing the number of people with prevalent multimorbidity (≥3 chronic conditions) as projected from our previous study (see online supplementary table SB).[@R16]

![Incidence rates (per 1000 person-years) of two chronic conditions (second condition in a dyad) and of three chronic conditions (third condition in a triad) in men and women separately (A and C), and stratified by ethnicity (B and D).](bmjopen2014006413f02){#BMJOPEN2014006413F2}

In the set of sensitivity analyses in which we combined hyperlipidaemia and hypertension as a single condition, we observed a slight decrease in the incidence of two chronic conditions and of three chronic conditions compared with the primary analyses. The overall incidence rate of two conditions decreased from 35.0 to 34.0/1000 person-years in men and from 40.3 to 40.0/1000 person-years in women. The incidence rate of three conditions decreased from 24.7 to 22.5/1000 person-years in men and from 28.5 to 27.0/1000 person-years in women (incidence rates non-standardised; data not shown in the tables). For both two and three conditions, the decrease in incidence was more sizeable in men than in women.

Incidence of dyads and triads {#s3c}
-----------------------------

[Table 3](#BMJOPEN2014006413TB3){ref-type="table"} shows the incidence of the most common dyads or triads of chronic conditions in seven age strata and for men and women separately. As expected, the incidence of dyads and triads varied extensively with age. For example, the most common incident dyad in persons 0--19 years was depression and asthma (1.8/1000 person-years in boys or men and 2.9/1000 person-years in girls or women). By comparison, the most common dyad in persons ≥80 years was hypertension and cancer in men (18.9/1000 person-years), and hypertension and arthritis in women (27.7/1000 person-years). Similarly, the most common incident triad of conditions in persons aged 0--19 years was depression, asthma and substance abuse disorders in both sexes. By comparison, the most common incident triads in persons ≥80 years were hypertension, cancer and arrhythmia in men, and hyperlipidaemia, hypertension and arthritis in women.

###### 

Incidence rates (per 1000 person-years) and composition of the most common dyads and triads of chronic conditions in persons living in Olmsted County, Minnesota, by age and sex.

  -----------------------------------------------------------------------------------------------------------------------------------
  Age (years)\   Dyad         Triad                                                                                      
  Rank \*                                                                                                                
  -------------- ------------ ------------ ------------- ------------ ------------------ ------------ ------------------ ------------
  0--19                                                                                                                  

   1             DEP---AST    1.8 (257)    DEP---AST     2.9 (395)    DEP---AST---SUB    0.4 (53)     DEP---AST---SUB    0.4 (62)

   2             DEP---SUB    1.3 (178)    DEP---SUB     1.8 (240)    DEP---AST---COPD   0.1 (17)     DEP---AST---COPD   0.3 (39)

   3             AST---COPD   0.9 (122)    AST---COPD    0.7 (91)     DEP---SUB---SZO    0.1 (8)      DEP---ARR---AST    0.2 (27)

   4             AST---SUB    0.4 (56)     DEP---ARR     0.4 (50)     LIP---DEP---AST    \<0.1 (7)    DEP---ARR---SUB    0.1 (13)

   5             DEP---ARR    0.1 (21)     DEP---COPD    0.4 (48)     3-way tie¶         \<0.1 (6)    DEP---SUB---COPD   0.1 (12)

  20--39                                                                                                                 

   1             DEP---SUB    3.5 (525)    DEP---AST     3.4 (531)    DEP---AST---SUB    0.4 (73)     DEP---AST---SUB    0.8 (134)

   2             LIP---HTN    1.4 (207)    DEP---SUB     2.9 (463)    DEP---SUB---SZO    0.4 (69)     DEP---AST---COPD   0.7 (121)

   3             DEP---AST    1.1 (174)    DEP---CAN     2.0 (309)    LIP---HTN---DIA    0.4 (65)     DEP---ARR---AST    0.4 (77)

   4             LIP---DEP    1.0 (155)    LIP---DEP     1.7 (267)    DEP---ARR---SUB    0.3 (46)     DEP---SUB---COPD   0.3 (61)

   5             LIP---DIA    0.9 (137)    DEP---ARR     1.4 (222)    LIP---HTN---DEP    0.3 (45)     LIP---DEP---AST    0.3 (58)

  40--49                                                                                                                 

   1             LIP---HTN    7.0 (580)    LIP---DEP     4.1 (354)    LIP---HTN---DIA    3.1 (294)    LIP---HTN---DIA    1.4 (147)

   2             LIP---DIA    4.4 (363)    LIP---HTN     3.6 (308)    LIP---HTN---DEP    1.2 (115)    LIP---HTN---DEP    1.1 (114)

   3             LIP---DEP    3.5 (285)    DEP---ART     2.6 (224)    LIP---HTN---ART    0.9 (84)     LIP---DEP---DIA    1.0 (99)

   4             LIP---ART    2.4 (198)    DEP---CAN     2.6 (224)    LIP---HTN---CAD    0.9 (83)     LIP---DEP---ART    0.8 (84)

   5             DEP---SUB    1.9 (157)    HTN---DEP     2.4 (203)    LIP---DEP---DIA    0.8 (74)     LIP---DEP---AST    0.6 (63)

  50--59                                                                                                                 

   1             LIP---HTN    14.5 (757)   LIP---HTN     9.8 (540)    LIP---HTN---DIA    7.2 (504)    LIP---HTN---DIA    3.9 (300)

   2             LIP---DIA    8.7 (455)    LIP---ART     6.5 (359)    LIP---HTN---ART    3.5 (242)    LIP---HTN---ART    3.0 (232)

   3             LIP---ART    6.7 (351)    LIP---DEP     5.9 (325)    LIP---HTN---CAD    3.0 (208)    LIP---HTN---DEP    2.4 (185)

   4             LIP---CAN    4.6 (241)    DEP---ART     4.8 (265)    LIP---HTN---DEP    1.9 (131)    LIP---DEP---ART    2.4 (180)

   5             HTN---DIA    4.4 (227)    LIP---CAN     4.5 (246)    LIP---HTN---ARR    1.7 (117)    LIP---HTN---CAN    1.8 (136)

  60--69                                                                                                                 

   1             LIP---HTN    23.4 (460)   LIP---HTN     18.8 (400)   LIP---HTN---DIA    11.6 (366)   LIP---HTN---ART    10.3 (363)

   2             LIP---DIA    11.5 (226)   LIP---ART     15.5 (330)   LIP---HTN---ART    6.8 (214)    LIP---HTN---DIA    7.4 (263)

   3             LIP---ART    11.4 (224)   HTN---ART     10.4 (220)   LIP---HTN---CAD    6.3 (200)    LIP---HTN---CAN    4.6 (164)

   4             LIP---CAN    10.0 (196)   LIP---CAN     6.8 (145)    LIP---HTN---CAN    4.9 (155)    LIP---ART---CAN    2.9 (102)

   5             HTN---DIA    8.6 (169)    LIP---DIA     6.4 (135)    LIP---HTN---ARR    3.4 (106)    LIP---DIA---ART    2.7 (95)

   6             HTN---ART    7.7 (152)    ART---CAN     4.9 (105)    LIP---DIA---ART    2.9 (91)     LIP---HTN---DEP    2.6 (93)

   7             LIP---CAD    6.9 (136)    LIP---OST     4.9 (105)    LIP---ART---CAN    2.6 (82)     LIP---DEP---ART    2.5 (89)

   8             HTN---CAN    6.2 (121)    HTN---CAN     4.8 (103)    LIP---DIA---CAD    2.4 (76)     LIP---ART---ARR    2.3 (83)

   9             ART---CAN    4.5 (89)     HTN---DIA     4.6 (97)     HTN---DIA---ART    2.2 (71)     LIP---HTN---OST    2.2 (79)

   10            LIP---ARR    4.5 (88)     LIP---DEP     4.4 (94)     LIP---ARR---CAD    2.2 (68)     HTN---DIA---ART    2.2 (77)

  70--79                                                                                                                 

   1             LIP---HTN    19.1 (104)   LIP---HTN     26.0 (173)   LIP---HTN---CAN    11.9 (127)   LIP---HTN---ART    15.7 (214)

   2             HTN---CAN    18.9 (103)   HTN---ART     18.5 (123)   LIP---HTN---DIA    10.4 (111)   LIP---HTN---DIA    9.8 (134)

   3             LIP---CAN    15.0 (82)    LIP---ART     15.5 (103)   LIP---HTN---CAD    9.7 (103)    LIP---HTN---CAN    6.0 (82)

   4             HTN---ART    13.2 (72)    LIP---OST     9.0 (60)     LIP---HTN---ART    9.4 (100)    LIP---ART---CAN    5.4 (74)

   5             ART---CAN    11.6 (63)    HTN---CAN     8.9 (59)     LIP---HTN---ARR    5.5 (58)     HTN---ART---CAN    5.2 (71)

   6             LIP---ART    11.6 (63)    HTN---OST     8.3 (55)     HTN---ART---CAN    4.9 (52)     LIP---ART---OST    5.2 (71)

   7             HTN---DIA    10.1 (55)    ART---CAN     8.1 (54)     LIP---ART---CAN    4.7 (50)     LIP---HTN---OST    4.6 (63)

   8             HTN---ARR    9.9 (54)     ART---OST     7.8 (52)     HTN---CAN---ARR    4.2 (45)     LIP---HTN---ARR    4.5 (62)

   9             LIP---CAD    7.7 (42)     HTN---DIA     7.8 (52)     HTN---ART---ARR    4.1 (44)     HTN---ART---OST    4.0 (55)

   10            LIP---DIA    7.7 (42)     LIP---CAN     7.8 (52)     LIP---DIA---CAN    4.1 (44)     2-way tie\*\*      3.4 (47)

  ≥80                                                                                                                    

   1             HTN---CAN    18.9 (30)    HTN---ART     27.7 (80)    HTN---CAN---ARR    8.7 (28)     LIP---HTN---ART    10.3 (66)

   2             HTN---ARR    17.6 (28)    LIP---HTN     23.2 (67)    LIP---HTN---CAN    7.7 (25)     HTN---ART---OST    9.8 (63)

   3             HTN---ART    14.5 (23)    HTN---ARR     17.7 (51)    HTN---ART---CAN    7.4 (24)     HTN---ART---CAN    9.2 (59)

   4             ART---ARR    12.0 (19)    HTN---CAN     15.2 (44)    LIP---HTN---ART    6.2 (20)     HTN---ART---ARR    9.0 (58)

   5             CAN---ARR    12.0 (19)    HTN---OST     14.9 (43)    LIP---HTN---ARR    5.9 (19)     LIP---HTN---OST    5.9 (38)

   6             HTN---CAD    10.1 (16)    HTN---DEM     11.8 (34)    ART---CAN---ARR    5.3 (17)     LIP---HTN---DIA    5.0 (32)

   7             LIP---HTN    10.1 (16)    ART---CAN     10.0 (29)    HTN---ART---ARR    5.3 (17)     LIP---HTN---ARR    4.7 (30)

   8             ART---CAN    8.8 (14)     ART---OST     9.7 (28)     HTN---CAN---CAD    5.0 (16)     LIP---HTN---CAN    4.5 (29)

   9             CAN---CAD    8.8 (14)     HTN---CKD     7.6 (22)     LIP---HTN---CAD    5.0 (16)     ART---CAN---OST    4.4 (28)

   10            HTN---DEM    8.8 (14)     3-way tie††   7.3 (21)     LIP---ART---CAN    4.6 (15)     LIP---HTN---CAD    3.9 (25)
  -----------------------------------------------------------------------------------------------------------------------------------

\*Rank order from the most frequent to the least frequent incident dyad or triad. For the younger age groups (through age 59 years), we reported the 5 most frequent incident combinations; for the older age groups (60 years and older), we reported the 10 most frequent incident combinations.

†ARR, cardiac arrhythmias; AST, asthma; ART, arthritis; AUT, autism spectrum disorder; CAN, cancer; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CHF, congestive heart failure; DEM, dementia; DEP, depression; DIA, diabetes; HEP, hepatitis; HTN, hypertension; LIP, hyperlipidaemia; OST, osteoporosis; SUB, substance abuse disorders; STR, stroke; SZO, schizophrenia.

‡Incidence rates per 1000 person-years. Rates can be calculated by dividing the number of incident persons in parentheses by the person-years at risk of two conditions from each age-specific and sex-specific stratum for all ethnic groups combined in [table 1](#BMJOPEN2014006413TB1){ref-type="table"}.

§Incidence rates per 1000 person-years. Rates can be calculated by dividing the number of incident persons in parentheses by the person-years at risk of three conditions from each age-specific and sex-specific stratum for all ethnic groups combined in [table 2](#BMJOPEN2014006413TB2){ref-type="table"}.

¶Three-way tie for the rank 5 triad in men ages 0--19 years: (1) AST-SUB-COPD; (2) DEP-ARR-SUB; (3) DEP-AST-DEM.

\*\*Two-way tie for the rank 10 triad in women ages 70--79 years: (1) HTN-ART-ARR; (2) LIP-CAN-OST.

††Three-way tie for the rank 10 dyad in women ages ≥80 years: (1) ART-ARR; (2) HTN-DIA; (3) LIP-ART.

As expected, the incidence of dyads and triads also varied by sex. In some instances, the composition of the dyads or triads was the same for men and women, but the magnitude of the incidence rate was different. In other instances, the magnitude of the incidence rate was similar in men and women, but the composition of the dyads and triads varied by sex. For example, the most common incident dyad in persons aged 60--69 years was hyperlipidaemia and hypertension in both sexes, but the incidence rate was higher in men compared to women (23.4/1000 person-years vs 18.8/1000 person-years). By contrast, the incidence rates of the most common triads in persons aged 60--69 years were similar in men and women (11.6/1000 vs 10.3/1000 person-years); however, they included different conditions ([table 3](#BMJOPEN2014006413TB3){ref-type="table"}).

Discussion {#s4}
==========

Statement of the principal findings {#s4a}
-----------------------------------

The burden of multimorbidity in the USA is high, and is increasing with an aging population and with improvements in survival. We leveraged a unique longitudinal data resource covering an entire, stable and geographically defined population to examine the incidence of multimorbidity across all ages. The incidence of two chronic conditions and the incidence of three chronic conditions increased steeply with older age, and the overall risk was similar in men and women. However, the number of people who developed multimorbidity before age 65 was more than four times greater than the number of people who developed multimorbidity after age 65 (28 378 vs 6214; [table 2](#BMJOPEN2014006413TB2){ref-type="table"}). The incidence of multimorbidity was highest in Blacks and lowest in Asians. Finally, as expected, the combinations of conditions in incident dyads and triads differed extensively by age and by sex. These results have important implications for identifying individuals at higher risk of developing multimorbidity at different ages. These data are also a first step toward understanding the causes and the consequences of multimorbidity.

Strengths and limitations {#s4b}
-------------------------

A unique strength of our study was the ability to measure the incidence of multimorbidity documented in medical records across seven age groups and for an entire, geographically defined population. We used historical data to exclude individuals with prevalent multimorbidity at baseline as well as to follow individuals over a long period of time to accurately document the development of incident multimorbidity. In total, our findings reflect 19 years of data accumulation (5 years before and 14 years after the baseline date).

Unfortunately, there is no standard definition of multimorbidity. Previous studies have included a wide range of chronic conditions and a wide range of time frames. We defined multimorbidity using the 20 conditions selected by US-DHHS, which were chosen because they 'meet the definition for chronicity, are prevalent \[common\], and are potentially amenable to public health or clinical interventions or both.'[@R23] However, this definition provides equal weight to each of the 20 conditions without considering the impact of combinations of specific conditions on the quality of life of patients, the complexity of their joint management and the severity of their long-term outcomes. In addition, this list does not include a number of conditions that may have a significant impact on the burden of multimorbidity in older participants (eg, hearing and vision problems). Such conditions should be considered in future studies of multimorbidity. By contrast, the list includes some conditions that were less common in the general population. For example, autism appeared as part of an incident dyad in only 31 persons, and HIV infection in only 41 persons. Therefore, further efforts are needed to refine the list of the most relevant conditions to study multimorbidity, recognising that the most relevant conditions will vary depending on the age and sex of the population.

Some of the dyads and triads derived by the combination of the 20 conditions selected by the US-DHHS may have a much stronger impact on the complexity of clinical management than others.[@R27] Therefore, some dyads or triads may be particularly costly for the health system, harder for patients to manage by themselves, less amenable to a single disease approach to care (eg, telemonitoring for heart failure), and may have a stronger effect on functionality, severity of symptoms and risk of death. In addition, social factors (eg, inadequate insurance, low education) and behavioural factors (eg, poor diet) not reflected in the list of 20 US-DHHS conditions may be as important as, or more important than, the 20 conditions in determining the complexity of clinical management and long-term outcomes.[@R27]

For example, because hyperlipidaemia and hypertension are typically asymptomatic, and are often diagnosed as the result of routine screening, their combination is likely to have a much lower impact on the life of the patient than the combination of schizophrenia and heart failure. However, both combinations are considered multimorbidity by the US-DHHS definition. Our sensitivity analyses highlight this problem. As expected, when hyperlipidaemia and hypertension were considered as a single condition, the overall incidence of multimorbidity decreased. The decreases were relatively small but were more sizeable in men than in women. These findings emphasise the importance of reaching consensus on the list of conditions to be used to define multimorbidity. However, it is difficult to assess the utility of the 20 conditions included in the US-DHHS list without also understanding how different combinations of these conditions impact long term outcomes. Therefore, we plan to continue this initial incidence study with further analyses to assess which combinations of conditions have the greatest impact on adverse outcomes, including patient quality of life and complexity of clinical management.[@R27]

We defined incident multimorbidity as the date on which a person met the criteria for a second condition or for a third condition. We used an approach similar to that used in the definition of the onset of metabolic syndrome (reaching three of five components of the syndrome).[@R28] [@R29] This simple operational definition of incident multimorbidity should be easy to replicate and should facilitate future comparisons with other populations.

Potential limitations of our study include the inability to validate the ICD-9 codes. It was not possible to confirm all diagnoses for the entire study population, and some ICD-9 codes may have been assigned in error (eg, 'rule out' diagnostic codes). To reduce the likelihood of a single ICD-9 code error, we required two or more diagnosis codes separated by more than 30 days for a person to be defined as having a condition.[@R30] However, if a person received a valid code and was lost to follow-up or died rapidly after diagnosis, we may have underestimated the incidence of some of the conditions. In addition, we used diagnosis date as a proxy for the true date of onset of the condition.

Some individuals may have moved into Olmsted County after having been diagnosed with one or more chronic conditions elsewhere. If those persons continued to receive care within the REP for a number of years, we captured their chronic condition at the time of subsequent healthcare visits. However, we did not know the true date of onset for the condition, and the sequence of accumulation of conditions could be distorted. Since the population of Olmsted County is stable, particularly among persons who are 40 years of age or older,[@R19] we do not expect a major distortion of the multimorbidity incidence rates observed in this study due to migration.

Finally, our study focused on a single geographically defined US population, and the incidence of multimorbidity may differ in other populations. However, the demographic and socioeconomic characteristics of our population are similar to those of the upper Midwest of the USA,[@R20] and the prevalence of multimorbidity in persons 65 years of age or older was similar in our population compared with the entire US Medicare population.[@R16] Replication of this study in other populations in the USA and worldwide will allow for useful comparisons.[@R31]

Comparison with other studies {#s4c}
-----------------------------

A number of studies have described the prevalence of multimorbidity in various populations; [@R1] [@R7] however, few studies have described the incidence of multimorbidity, and no incidence studies are available for the US. In 1998, van den Akker *et al*[@R32] estimated the 1 year incidence of multimorbidity in patients from a network of family practices in the Netherlands. Incident multimorbidity was defined as the new development of at least 2 of 335 diagnostic categories within a 1-year period. Overall, 7.9% of their population developed one new disease and 1.3% developed two or more new diseases in 1 year. The proportion of people who developed two or more new conditions increased with older age, but did not differ substantially by sex. It is difficult to compare our results directly to the Dutch findings because of methodological differences (eg, number of conditions considered and time frame), and because it is not clear whether some of the participants in the Dutch study already had one or more conditions at baseline. However, we observed similar patterns of increasing incidence with older age, and limited differences between men and women in overall incidence.

More recently, Melis *et al*[@R33] assessed the incidence of multimorbidity in Swedish people aged 75 years or older at baseline who participated in a longitudinal cohort study. Incident multimorbidity was defined as the development of at least 2 of 39 chronic conditions during 3 years of follow-up. Participants with none of the 39 chronic conditions at baseline had a multimorbidity incidence rate of 12.6 per 100 person-years, and patients with one of the 39 conditions at baseline had an incidence rate of 32.9 per 100 person-years. Although we examined fewer conditions than the Swedish group (20 vs 39), and the ascertainment of incident conditions was different (medical records data vs survey methods), our incidence rates of multimorbidity in participants aged 75 years or older were similar (19.1 per 100 person-years in people with no conditions at baseline and 38.9 per 100 person-years in persons with one condition at baseline; both sexes combined; data not shown).

Meaning of the study {#s4d}
--------------------

To understand the importance of these findings, we draw an analogy with the difference between prevalence and incidence in epidemiological studies considering one disease at a time.[@R34] [@R35] Incidence is the direct measure of the risk of people to develop a given disease, whereas prevalence is the percent of people affected by the same disease at one point in time, and reflects both the effect of incidence and the effect of survival after the onset of the disease.[@R34] [@R35] Similarly, the prevalence of multimorbidity gives us a static picture of the population; however, prevalence may be misleading when studying the mechanisms of multimorbidity. For example, a higher prevalence of multimorbidity in women than in men may be due to a higher risk of women developing multimorbidity, or to a longer survival of women affected by multimorbidity.[@R16] Similarly, studying outcomes among persons with prevalent multimorbidity may be clinically relevant, but may not clarify the outcomes of multimorbidity at the population level (eg, survival bias and inability to study the effect of the duration of multimorbidity).

Prior studies of the prevalence of multimorbidity have shown a dramatic increase in the number of people living with two or more chronic conditions at older ages.[@R1] [@R7] However, the high prevalence of multimorbidity in the older population implies that relatively few older individuals remain at risk of developing multimorbidity. Overall, among persons aged 80 years or older at baseline, only 891 out of 3710 (24%) were at risk of developing two chronic conditions (the other 76% already had 2 or more of the 20 conditions). Although the persons who reached 80 years of age or older and remained free of multimorbidity were a particularly resilient group, they had a higher risk of developing subsequent multimorbidity compared with younger persons.

We also found that the total number of people who developed multimorbidity before age 65 years was more than four times greater than the number of people who developed multimorbidity at ages 65 or older (28 378 vs 6214). These data emphasise the need to target preventive efforts at much younger ages, but represent only a first step toward future research to identify the social, behavioural and clinical risk and protective factors for multimorbidity.

We found important differences in the incidence of multimorbidity by ethnicity. The age standardised incidence rates of multimorbidity were higher in Blacks and lower in Asians compared to Whites. Our findings are consistent with previous studies that showed a higher prevalence of multimorbidity in Blacks compared to Whites, but a lower prevalence of multimorbidity in Asians.[@R8] [@R16] [@R36] Our data suggest that some of these differences in prevalence may be attributed to differences in the incidence of the conditions among different ethnic groups. However, differential survival may also contribute to the differences in prevalence. In turn, differences in incidence and in prevalence may both be influenced by socioeconomic factors, lifestyle behaviours, social environment and healthcare access. Further research is needed to better characterise these disparities and to identify the causal mechanisms that contribute to different development of chronic conditions and to different survival.

As expected, the incidence and the composition of the dyads and triads of conditions varied extensively across age and sex strata. For example, women 20 years of age or older were more likely to have depression as a component of their incident multimorbidity dyads and triads compared to men. Such differences may lead to different long-term outcomes in men and women. Therefore, these data are useful to understand how multimorbidity develops, and are an important first step toward future research. In particular, such incident data are necessary to study the chronological order of acquisition of multiple chronic conditions in different age, sex and ethnic strata.

Incidence data are also necessary to determine whether the differential order of acquisition is associated with a different risk of adverse long-term outcomes such as hospitalisations, emergency department visits or death. For example, it is not clear whether acquiring depression prior to arthritis results in worse long-term outcomes compared with acquiring arthritis prior to depression. Future studies are also needed to understand how additional chronic conditions accumulate after the development of a second and third condition. Finally, the incidence of specific dyads and triads reflects the incidence of the individual conditions in specific age and sex groups. Many of these dyads and triads are expected to develop simply by chance. Therefore, future studies are needed to identify the dyads and triads that co-occur beyond chance. Identification of incident dyads and triads that reflect shared aetiological mechanisms or shared risk factors may lead to combined treatment or prevention strategies.

Conclusions and clinical implications {#s4e}
-------------------------------------

It is important and urgent to understand the causes and the consequences of multimorbidity to inform efforts to delay and prevent disease onset, and to develop effective strategies for caring for patients with multimorbidity. We studied the incidence of multimorbidity across all ages, separately in men and women, and in three ethnic groups in a geographically defined US population. The incidence of multimorbidity increased steeply with older age and was higher in Blacks but lower in Asians compared to Whites. Men and women had a similar overall risk, but the combinations of conditions within dyads and triads varied extensively by age and by sex. These data represent an important first step toward identifying conditions that co-occur more frequently than by chance alone, identifying specific risk factors for multimorbidity, understanding how chronic conditions accumulate over time and toward identifying combinations of conditions that predict adverse outcomes.
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